Feedback
Settings

Settings

Goto Application

1. WO2022011155 - BIOMARKERS FOR IDENTIFYING RELAPSES IN MULTIPLE SCLEROSIS

Submit observation
PermaLink
Publication Number WO/2022/011155
Publication Date 13.01.2022
International Application No. PCT/US2021/040912
International Filing Date 08.07.2021
IPC
A61P 21/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
A61P 25/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/53 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/68 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
CPC
A61P 21/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 2333/70596
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
G01N 2800/285
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
28Neurological disorders
285Demyelinating diseases; Multipel sclerosis
Applicants
  • OKLAHOMA MEDICAL RESEARCH FOUNDATION [US]/[US]
  • THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA [US]/[US]
Inventors
  • AXTELL, Robert
  • KUMAR, Gaurav
  • AGASING, Agnieshka
Agents
  • FLORES, Edwin S.
  • CHALKER, Daniel, J.
Priority Data
63/049,85909.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) BIOMARKERS FOR IDENTIFYING RELAPSES IN MULTIPLE SCLEROSIS
(FR) BIOMARQUEURS POUR L'IDENTIFICATION DES RECHUTES DANS LA SCLÉROSE EN PLAQUES
front page image
Abstract
(EN) The present invention includes a method of predicting and/or treating a recurrence of MS treating a patient with multiple sclerosis, the method comprising: obtaining a hematopoietic cell sample from a patient suspected of having a recurrence of multiple sclerosis (MS), wherein the patient was in relapse for MS; determining the number of CD19+, CD24+, CD38+ transitional B cells in the hematopoietic cell sample, and a level of expression of neurofilament light (NFL) and interleukin-1β (IL-1β), which is predictive of a recurrence of MS; and treating the MS patient with recurrence until there is an increase in CD19+, CD24+, CD38+ transitional B cells and/or a decrease in a level of expression of NFL and interleukin-1β (IL-1β) when compared to an untreated MS control sample, an unresponsive MS control sample, or an MS patient with long-term stable disease sample.
(FR) La présente invention concerne une méthode de prédiction et/ou de traitement d'une rechute de SEP chez un patient atteint de sclérose en plaques, la méthode comprenant les étapes consistant à : prélever un échantillon de cellules hématopoïétiques chez un patient chez lequel on soupçonne une rechute de sclérose en plaques (SEP), le patient subissant une poussée de SEP; déterminer le nombre de lymphocytes B transitoires CD19+, CD24+, CD38+ dans l'échantillon de cellules hématopoïétiques, et un niveau d'expression de protéines légères de neurofilaments (NFL) et d'interleukine-1β (IL-1β), qui est révélateur d'une rechute de la sclérose en plaques; et traiter le patient atteint de SEP présentant une rechute jusqu'à augmentation des lymphocytes B transitoires CD19+, CD24+, CD38+ et/ou diminution du niveau d'expression des NFL et de l'interleukine-1β (IL-1β) par comparaison avec un échantillon témoin SEP non traité, un échantillon SEP témoin non réactif, ou un échantillon d'un patient souffrant d'une SEP stabilisée depuis longtemps.
Latest bibliographic data on file with the International Bureau
# -